We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AnaptysBio, Inc. (ANAB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AnaptysBio, Inc. is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AnaptysBio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 11.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ANAB has returned about 4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 0.5% on a year-to-date basis. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Castle Biosciences, Inc. (CSTL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 38.1%.
Over the past three months, Castle Biosciences, Inc.'s consensus EPS estimate for the current year has increased 93.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 504 individual stocks and currently sits at #65 in the Zacks Industry Rank. Stocks in this group have lost about 7% so far this year, so ANAB is performing better this group in terms of year-to-date returns. Castle Biosciences, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track AnaptysBio, Inc. and Castle Biosciences, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AnaptysBio, Inc. (ANAB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AnaptysBio, Inc. is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AnaptysBio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 11.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ANAB has returned about 4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 0.5% on a year-to-date basis. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Castle Biosciences, Inc. (CSTL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 38.1%.
Over the past three months, Castle Biosciences, Inc.'s consensus EPS estimate for the current year has increased 93.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 504 individual stocks and currently sits at #65 in the Zacks Industry Rank. Stocks in this group have lost about 7% so far this year, so ANAB is performing better this group in terms of year-to-date returns. Castle Biosciences, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track AnaptysBio, Inc. and Castle Biosciences, Inc. These stocks will be looking to continue their solid performance.